

## Biognosys to Participate in Capital One Spatial Biology & Proteomics Healthcare Disruptors Summit

Biognosys CEO Oliver Rinner, Ph.D., will discuss the advances in mass spectrometry-based proteomics and Biognosys' technology and solutions

**September 21, 2022. ZURICH and CAMBRIDGE, Mass.** Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they are participating in the upcoming Capital One Spatial Biology & Proteomics Healthcare Disruptors Summit, taking place virtually on Wednesday, September 28.

Biognosys' CEO and co-founder, Oliver Rinner, Ph.D., is scheduled to participate in two panel discussions.

### **Proteomics Expert Panel: "Everything You Wanted to Know, But Were Afraid to Ask"**

(11:30 a.m. ET / 5:30 p.m. CET)

- **Moderator:** Phil Lorenzi, Ph.D., Associate Professor and Director of the Proteomics and Metabolomics Core Facility at **The University of Texas MD Anderson Cancer Center**.
- **Panelists:** Oliver Rinner, Ph.D., CEO at **Biognosys**, Sujal Patel, CEO of **Nautilus**, and Roy Smythe, M.D, CEO at **SomaLogic**.

### **Spatial Biology & Proteomics Executive Panel: Technology and Platforms Showcase**

(1:00 p.m. ET / 7:00 p.m. CET)

- **Panelists:** CEOs from **Akoya**, **Biognosys**, **Lunaphore**, **SomaLogic**, and **Standard BioTools**

The event further includes a panel on Spatial Biology/Single Cell, "The Final Frontier in Cell Exploration?" and a panel with Large Biopharma/Biotech Customers, highlighting the growing demand for Spatial Biology/Proteomics tools.

"I am excited to participate alongside other industry leaders in this high-quality event on healthcare disruption," **comments Oliver Rinner**. "I look forward to discussing how the proteomics field is revolutionizing life sciences research and how Biognosys' cutting-edge mass spectrometry-based proteomics solutions are propelling the development of innovative medicines and diagnostics."

Contact [Tim Chiang](#), Senior Research Analyst Healthcare / Biotechnology at Capital One Securities, to register.

A recording of the panel discussions will be made available at [biognosys.com/resources](http://biognosys.com/resources).

## About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys' unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit [biognosys.com](http://biognosys.com).

## Media Contact

### **Yves Serroen**

Head of Marketing and Communications

Phone +41 (0) 79 571 09 21

[yves.serroen@biognosys.com](mailto:yves.serroen@biognosys.com)